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Background: The aim of this study was to investigate the associations of two nontraditional glycemic markers,
glycated albumin (GA) and 1,5-anhydroglucitol (1,5-AG), as well as glycated hemoglobin A1c (HbA1c) with coronary
artery disease (CAD).
Methods: In total, 272 subjects (178 men and 94 postmenopausal women) were enrolled in this study. All of them
underwent coronary angiography which was used to diagnose CAD. The severity of coronary artery stenosis was
assessed by the coronary stenosis index (CSI). GA and 1,5-AG were assayed using the enzymatic method, and
HbA1c was detected by high-pressure liquid chromatography.
Results: The HbA1c and GA levels were significantly higher in CAD group than those in non-CAD group (both P < 0.01).
While the 1,5-AG level was significantly lower in CAD group than that in non-CAD group (P < 0.05). After adjustment for
traditional risk factors of CAD, HbA1c, 1,5-AG, and GA, multivariate logistic regression analysis showed that GA was an
independent risk factor for CAD (odds ratio = 1.143, 95% confidence interval: 1.048-1.247, P = 0.002). With CSI as a
dependent variable, multiple stepwise regression analysis demonstrated an independent positive correlation between
GA and CSI (standardized β = 0.184, P = 0.003), beyond gender, age, and lipid-lowering therapy, after adjustment for
traditional risk factors of CAD, HbA1c, 1,5-AG, and GA.
Conclusions: GA was more closely correlated with CAD than HbA1c and 1,5-AG in a Chinese population with high risk
of CAD.
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1,5-anhydroglucitolBackground
Diabetes mellitus is a coronary artery disease (CAD) risk
equivalent. Abnormalities in glucose metabolism give rise
to an increased incidence of CAD, and blood glucose level
is considered to be a continuous risk factor for cardiovas-
cular disease [1]. Clinical studies have revealed that ath-
erosclerosis, a chronic inflammatory process, is activated
not after the diagnosis of diabetes, but rather in the early* Correspondence: zhoujian@sjtu.edu.cn; wpjia@sjtu.edu.cn
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unless otherwise stated.stage of hyperglycemia, even when the glycemic level is
not high enough to indicate the presence of diabetes.
Furthermore, the process of atherosclerosis is accelerated
in patients with elevated blood glucose level [2]. Thus,
research exploring on the correlations of standard gly-
cemic marker [e.g., glycated hemoglobin A1c (HbA1c)]
and some nontraditional glycemic markers [e.g., glycated
albumin (GA), which reflects the blood glucose level dur-
ing the previous 2 to 3 weeks, and 1,5-anhydroglucitol
(1,5-AG), which reflects the blood glucose level during
the previous 1 to 2 weeks] with CAD to identify which
glycemic markers are more closely related to CAD is
of clinical importance for early screening and interven-
tion of CAD.s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with type 2 diabetes mellitus suggested that GA was su-
perior to HbA1c for identifying the presence and severity
of CAD [3-5]. Additionally, Ikeda, et al. [6] found that the
serum 1,5-AG level was more valuable than the HbA1c
level as a predictor of CAD in Japanese patients. To date,
however, few studies have simultaneously compared the
relationships of the presence of CAD between HbA1c,
GA, and 1,5-AG levels in Chinese population. In the
present study, we used coronary angiography to diagnose
CAD and calculated the coronary stenosis index (CSI) to
assess the severity of coronary artery stenosis [7]. The goal
of this study was to investigate the associations of HbA1c,
GA, and 1,5-AG with the presence and severity of CAD




The subjects in this study were recruited from the Depart-
ment of Cardiology of Shanghai Jiao Tong University Af-
filiated Sixth People’s Hospital from July 2008 to January
2010. All subjects underwent coronary angiography and
provided complete clinical data. We excluded subjects
with the following factors affecting HbA1c, GA, and 1,5-
AG measurements and analyses: myocardial infarction
within 3 months, history of coronary artery bypass grafting
or percutaneous coronary intervention within 6 months;
congestive heart failure; acute infection; psychosis; auto-
immune disease; hematopathy; liver or renal dysfunction;
hyperthyroidism or hypothyroidism; history of malig-
nancy, severe trauma or gastrectomy; or use of traditional
Chinese medicine.
All subjects completed a standard questionnaire about
their disease history, medication history, family history of
CAD and smoking status along with the complete results
of their physical examination, blood pressure measure-
ment, and parameters of glucose and lipid metabolism. A
current smoking status was defined as regular smoking or
smoking at least one cigarette per day for more than
6 months [8]. Finally, 272 subjects (age range, 38-86 yr,
mean 65.7 ± 10.2 yr), including 178 men and 94 postmeno-
pausal women, were enrolled in this study. The diagnosis of
diabetes was established according to the criteria proposed
by the World Health Organization in 1999 [9]. This study
was approved by the local Ethics Committee of Shanghai
Jiao Tong University Affiliated Sixth People’s Hospital, and
all subjects provided written informed consent.
Anthropometric measurements
The body mass index (BMI) of each subject was calculated
as weight in kilograms divided by the square of height in
meters. Waist circumference (W) was measured in the
standing position midway between the lowest rib and theiliac crest. Blood pressure was detected with a mercury
sphygmomanometer after the subjects had rested for
10 minutes.
Laboratory measurements
Blood samples of all subjects were obtained in the morn-
ing after a 10-hour overnight fast. A 75-g oral glucose tol-
erance test was performed among subjects without history
of diabetes, while a 100-g carbohydrate test was carried
out for the known diabetic patients. The fasting plasma
glucose level (FPG) and 2-hour postprandial plasma glu-
cose level (2hPG) were assessed by the glucose oxidase
method. The serum creatinine level (Scr) and lipid profiles
including the triglyceride level (TG), total cholesterol level
(TC), low-density lipoprotein cholesterol level (LDL-c),
and high-density lipoprotein cholesterol level (HDL-c)
were quantified by enzymatic methods on a 7600-020
autoanalyzer (Hitachi, Tokyo, Japan). The serum C-
reactive protein level (CRP) was determined via particle-
enhanced immunonephelometry assay (Dade Behring Inc.,
Newark, NJ, USA). The fasting serum insulin level (FINS)
was determined via radioimmunoassay (Linco Research,
St. Charles, MO, USA) and was applied to calculate the
homeostasis model assessment-insulin resistance index
(HOMA-IR) as follows: HOMA-IR = FPG (mmol/L) ×
FINS (mU/L)/ 22.5 [10]. The estimated glomerular filtra-
tion rate (eGFR, mL/min/1.73 m2) was calculated accord-
ing to the following equation recommended by the
Modification of Diet in Renal Disease study: eGFR =
[186 × (Scr/88.4) -1.154 × (age) -0.203 × 0.742 (if women)] [11].
HbA1c was detected by high-pressure liquid chroma-
tography (Variant II hemoglobin analyzer; Bio-Rad,
Hercules, CA, USA) with inter- and intra-assay coeffi-
cients of variation of < 3.40% and < 2.60%, respectively.
GA was measured via a liquid enzymatic method (Lucica
GA-L; Asahi Kasei Pharma Corporation, Tokyo, Japan)
on a Glamour 2000 autoanalyzer (Molecular Devices,
Sunnyvale, CA, USA) with inter- and intra-assay coeffi-
cients of variation of < 5.10% and < 3.00%, respectively.
Finally, serum 1,5-AG was assayed by an enzymatic
method (GlycoMark; GlycoMark Inc., New York, NY,
USA) [12] on a 7600-120 autoanalyzer (Hitachi, Tokyo,
Japan) with inter- and intra-assay coefficients of vari-
ation of < 2.19% and < 1.54%, respectively.
Diagnosis of CAD
Coronary angiography was performed according to the
method of Judkins [13]. CAD was defined as the pres-
ence of a luminal diameter stenosis of ≥ 50% in the left
main coronary artery, left anterior descending artery or
its first diagonal branch, left circumflex artery or its first
obtuse marginal branch, and right coronary artery. Two
experienced cardiologists performed coronary angiog-
raphy on every participant and analyzed the images
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assessed by calculating the CSI; the severity of coronary
artery stenosis increased in parallel with the elevation of
the CSI [7].Statistical analysis
SPSS, version 16.0 was used for statistical analysis. All
variables underwent a normality test. Normally distrib-
uted data were expressed as the mean ± standard devi-
ation, while skewed data were expressed as the median
with interquartile range. For normally distributed data, in-
tergroup comparisons were carried out using the unpaired
Student’s t test; for skewed data, intergroup comparisons
were conducted using the Wilcoxon rank sum test. Inter-
group comparisons of categorical variables were carried




Age (years) 65.7 ± 10.2
BMI (kg/m2) 24.8 ± 3.1
W (cm) 90.4 ± 9.2
SBP (mmHg) 130 (120-148)
DBP (mmHg) 80 (70-85)
FPG (mmol/L) 5.4 (5.0-6.3)
2hPG (mmol/L) 8.6 (6.7-11.8)
HbA1c (%) 6.2 (5.7-6.8)
GA (%) 16.0 (14.0-19.0)
1,5-AG (μg/mL) 21.7 ± 10.1
TC (mmol/L) 4.4 ± 1.1
TG (mmol/L) 1.5 (1.1-2.2)
HDL-c (mmol/L) 1.1 (0.9-1.3)
LDL-c (mmol/L) 3.0 ± 0.9
eGFR (mL/min/1.73 m2) 89.0 ± 23.6
CRP (mg/L) 1.2 (0.6-3.1)
HOMA-IR 4.0 (2.8-5.9)
CSI 6 (2-12)
Smoking, n (%) 121 (44.5)
Diabetes ratio, n (%) 110 (40.4)
Family history of CAD, n (%) 116 (42.6)
Hypoglycemic therapy, n (%) 62 (22.8)
Anti-hypertensive therapy, n (%) 185 (68.0)
Lipid-lowering therapy, n (%) 76 (27.9)
CAD: Coronary artery disease; BMI: Body mass index; W: Waist circumference; SBP: S
glucose; 2hPG: 2-hour postprandial glucose; HbA1c: Glycated hemoglobin A1c; GA:
Triglyceride; HDL-c: High density lipoprotein cholesterol; LDL-c: Low density lipopro
protein; HOMA-IR: Homeostasis model assessment-insulin resistance index; CSI: Coro
For the subjects: aP < 0.05, CAD vs. non-CAD; aaP < 0.01, CAD vs. non-CAD. Data areand partial correlation analysis were conducted to explore
the relationships among different glycemic indicators.
Multivariate logistic regression analysis and multiple step-
wise regression analysis were performed to identify the in-
dependent factors influencing the presence and severity of
CAD. All the variables, which were traditional risk factors
for CAD, as well as the disease-related therapies, were
selected to enter into the regression analysis. All reported
P values were two-tailed, and P < 0.05 was considered sta-
tistically significant.Results
Clinical characteristics of the study participants
Of all 272 subjects, 194 (71.3%) were diagnosed with
CAD. As shown in Table 1, compared with non-CAD
group, subjects of CAD group were older and had higheror absence of CAD
Non-CAD CAD
(N = 78) (N = 194)
39/39 139/55aa
62.4 ± 10.0 67.0 ± 10.1aa
25.2 ± 3.2 24.6 ± 3.1
90.1 ± 9.4 90.5 ± 9.1
130 (120-143) 130 (120-150)
80 (70-88) 80 (70-83)
5.5 (5.1-6.0) 5.4 (5.0-6.5)
8.1 (6.0-9.9) 8.8 (6.7-12.5)a
5.9 (5.6-6.4) 6.2 (5.8-7.0)aa
15.0 (13.0-17.0) 16.0 (15.0-19.0)aa
23.9 ± 9.8 20.8 ± 10.1a
4.6 ± 1.0 4.3 ± 1.1a
1.6 (1.1-2.3) 1.5 (1.1-2.1)
1.1 (0.9-1.3) 1.0 (0.9-1.3)
3.1 ± 0.8 3.0 ± 1.0
92.2 ± 24.9 87.8 ± 23.0
1.4 (0.5-3.1) 1.2 (0.6-2.9)
3.9 (2.8-5.9) 4.0 (2.8-6.1)
0 (0-1) 9 (4-14)aa
29 (37.2) 92 (47.4)
24 (30.8) 86 (44.3)a
38 (48.7) 78 (40.2)
11 (14.1) 51 (26.3)a
51 (65.4) 134 (69.1)
11 (14.1) 65 (33.5)aa
ystolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma
Glycated albumin; 1,5-AG: 1,5-anhydroglucitol; TC: Total cholesterol; TG:
tein cholesterol; eGFR: Estimated glomerular filtration rate; CRP: C-reactive
nary stenosis index.
presented as mean ± standard deviation or median (interquartile range).
Ma et al. Cardiovascular Diabetology  (2015) 14:16 Page 4 of 7levels of 2hPG, HbA1c, GA, and CSI (all P < 0.05), along
with lower levels of 1,5-AG and TC (both P < 0.05),
while FPG did not differ significantly between the two
groups (P > 0.05). Subjects with CAD also exhibited a
higher ratio of diabetes, use of hypoglycemic agents, and
use of lipid-lowering drugs than subjects without CAD
(all P < 0.05).
Correlation analysis of glycemic markers
Spearman correlation analysis (Table 2) revealed that
1,5-AG was inversely related to FPG, 2hPG, HbA1c, and
GA (r = –0.417, –0.482, –0.504, and –0.421, respectively;
all P < 0.001), whereas GA was positively associated with
FPG, 2hPG, and HbA1c (r = 0.469, 0.591, and 0.619, re-
spectively; all P < 0.001). The relationships between gly-
cemic markers (FPG, 2hPG, HbA1c, GA, and 1,5-AG)
still existed in the partial correlation analysis after ad-
justment for age and gender (all P < 0.001).
Multivariate analysis of factors contributing to CAD
For multivariate logistic regression analysis, the presence
of CAD was a dependent variable; HbA1c, 1,5-AG, and
GA were separate independent variables. After adjust-
ment for traditional risk factors for CAD [gender, age,
BMI, W, systolic blood pressure (SBP), diastolic blood
pressure (DBP), TC, TG, HDL-c, LDL-c, eGFR, CRP,
HOMA-IR, FPG, 2hPG, smoking status, family history
of CAD, hypoglycemic therapy, anti-hypertensive ther-
apy, and lipid-lowering therapy], the results showed that
HbA1c [odds ratio (OR) = 1.343, 95% confidence inter-
val (CI): 1.007-1.791, P = 0.044], 1,5-AG (OR = 0.957,
95% CI: 0.927-0.989, P = 0.008), and GA (OR = 1.143,
95% CI: 1.048-1.247, P = 0.002) were all the factors con-
tributing to CAD.
Next, we created two models with the presence of CAD
as the dependent variable to identify which indicator was
most closely associated with CAD (Table 3). The inde-








Adjust for age and gender
GA 0.709 < 0.001
1,5-AG –0.579 < 0.001
FPG 0.752 < 0.001
2hPG 0.697 < 0.001CAD and the glycemic markers (HbA1c, 1,5-AG, and
GA). The difference between the two models was the
selection of glycemic markers. Model 1 only analyzed
HbA1c and 1,5-AG and revealed that in addition to
gender, age, and lipid-lowering therapy, 1,5-AG was in-
dependently associated with CAD (OR = 0.957, 95% CI:
0.927-0.989, P = 0.008). However, when HbA1c, 1,5-AG,
and GA were simultaneously condensed into the equation
in Model 2, GA remained as an independent risk factor
for CAD (OR = 1.143, 95% CI: 1.048-1.247, P = 0.002).Factors influencing the severity of coronary artery
stenosis
Spearman correlation analysis showed that the CSI was
positively associated with 2hPG, HbA1c, and GA (r = 0.197,
0.259, and 0.258, respectively; all P < 0.01) and inversely as-
sociated with 1,5-AG (r = –0.155, P = 0.010). No relation-
ship was found between the CSI and FPG (r = 0.104,
P = 0.086). After adjustment for gender and age, the
CSI remained correlated with these glycemic markers
above (all P < 0.05) and even showed a positive associ-
ation with FPG (r = 0.135, P = 0.026).
A multiple stepwise regression model was used to analyze
the independent factors affecting the severity of coronary ar-
tery stenosis (Table 4). The dependent variable was the CSI,
and the independent variables were gender, age, BMI, W,
SBP, DBP, TC, TG, HDL-c, LDL-c, eGFR, CRP, HOMA-IR,
FPG, 2hPG, HbA1c, GA, 1,5-AG, smoking status, family
history of CAD, hypoglycemic therapy, anti-hypertensive
therapy, and lipid-lowering therapy. The results indicated
that beyond gender, age, and lipid-lowering therapy, GA
(standardized β = 0.184, P = 0.003) was independently corre-
lated with the CSI.Discussion
HbA1c measurement is internationally recognized as the
gold standard indicator of glycemic control, and thisandard (FPG, 2hPG, and HbA1c) glycemic markers
GA 1,5-AG
r P r P
- - - -
–0.421 <0.001 - -
0.469 <0.001 –0.417 <0.001
0.591 <0.001 –0.482 < 0.001
- - - -
–0.441 < 0.001 - -
0.609 < 0.001 –0.495 < 0.001
0.646 < 0.001 –0.525 < 0.001
Table 3 Multivariate logistic regression analysis of
independent factors associated with CAD
Independent variable β S.E. P OR 95% CI
Model 1
Gender (women) –1.211 0.339 < 0.001 0.298 0.153-0.579
Age 0.055 0.016 0.001 1.057 1.023-1.092
Lipid-lowering therapy 1.223 0.401 0.002 3.396 1.548-7.452
1,5-AG –0.044 0.017 0.008 0.957 0.927-0.989
Model 2
Gender (women) –1.101 0.334 0.001 0.332 0.173-0.640
Age 0.056 0.017 0.001 1.058 1.024-1.092
Lipid-lowering therapy 1.246 0.401 0.002 3.476 1.584-7.627
GA 0.134 0.044 0.002 1.143 1.048-1.247
Model 1: traditional risk factors for CAD (gender, age, BMI, W, SBP, DBP, TC, TG,
HDL-c, LDL-c, eGFR, CRP, HOMA-IR, FPG, 2hPG, smoking status, family history
of CAD, hypoglycemic therapy, anti-hypertensive therapy, lipid-lowering
therapy), HbA1c and 1,5-AG.
Model 2: traditional risk factors for CAD, HbA1c, 1,5-AG and GA.
Ma et al. Cardiovascular Diabetology  (2015) 14:16 Page 5 of 7indicator is widely used to monitor glucose level in pa-
tients with diabetes. In recent years, the applications of
HbA1c in the clinical setting have expanded to the
screening, diagnosis, and prognosis of diabetes, making
HbA1c a composite marker that combines a variety of
functions [14]. In addition, HbA1c has also been demon-
strated as an independent risk factor for cardiovascular
disease [15]. However, HbA1c, influenced by hemoglobin
update rate, drugs, and race, still bears some limitations
since it can only reflect the mean blood glucose level
over the previous 2 to 3 months. Unable to accurately
reflect short-term glycemic variability, HbA1c has de-
layed effects when applied in adjustment for glucose-
lowering treatments.
Some new indicators, such as GA and 1,5-AG, have
emerged during recent years and provide HbA1c with
complementary information. The study from Mukai,
et al. [16] suggested the potential applicabilities of GA
and 1,5-AG measurements as diagnostic tools for dia-
betes. GA, an early Amadori-type glycation protein of
the nonenzymatic glycation reaction between glucose
and serum albumin, is an index reflecting the average
glucose level over the previous 2 to 3 weeks. PreviousTable 4 Multiple stepwise regression analysis of CSI
Independent variable Standardized β t value P
Gender (women) –0.264 –4.349 < 0.001
Age 0.194 3.182 0.002
Lipid-lowering therapy 0.245 4.046 < 0.001
GA 0.184 3.039 0.003
Variables of the original model included: gender, age, BMI, W, SBP, DBP, TC,
TG, HDL-c, LDL-c, eGFR, CRP, HOMA-IR, FPG, 2hPG, HbA1c, GA, 1,5-AG, smoking
status, family history of CAD, hypoglycemic therapy, anti-hypertensive therapy
and lipid-lowering therapy.reports have demonstrated its advantage over HbA1c in
reflecting glycemic excursion [17]. In addition, GA is
strongly associated with incident diabetes and its micro-
vascular complications, with prognostic value compar-
able to HbA1c [18]. But several factors, including the
half-life of serum albumin, disorders such as thyroid dis-
ease and nephrotic syndrome, have been identified to
exert effects on GA. 1,5-AG is the C1 deoxy form of glu-
cofuranose and reflects the average blood glucose level
during the past 1 to 2 weeks. This indicator is reportedly
superior to HbA1c as a sensitive marker of postprandial
hyperglycemia when the glucose level is above the renal
glucose threshold [19,20]. 1,5-AG is known to be main-
tained at a steady-state level in the circulation, but
chronic liver disease, severe renal impairment, cystic fi-
brosis, and the history of gastrectomy are known to
affect 1,5-AG; however, there is few systemic report on
its relationship with other glycemic markers and diabetic
complications.
In our study, comparisons were performed for the first
time among the associations of HbA1c, GA, and 1,5-AG
with CAD in a Chinese population with high risk of
CAD. Significant differences in 2hPG, HbA1c, GA, and
1,5-AG, but not FPG, were noted between subjects with
and without CAD. All glycemic markers were highly cor-
related with each other. With respect to the ability of
these indicators to reflect the blood glucose level over a
certain period of time (HbA1c, the previous 2 to 3
months; GA, the previous 2 to 3 weeks; and 1,5-AG, the
previous 1 to 2 weeks), GA and 1,5-AG were more
closely correlated with CAD than was HbA1c. Addition-
ally, GA appeared to be independently associated with
the severity of coronary artery stenosis according to the
calculated CSI.
Persistent hyperglycemia, especially elevated postprandial
or postchallenge glucose level, may add to the risks of
micro- or macrovascular complications in patients with
diabetes [21]. After prospective analyses, the DECODE and
DECODA group found that 2hPG was superior to FPG as
a predictor of deaths from all causes and cardiovascular
disease [22,23]. Moreover, there is growing evidence sup-
porting links between postprandial hyperglycemia and oxi-
dative stress, carotid intima-media thickness as well as
endothelial dysfunction, all of which are recognized as
markers of cardiovascular disease [21,24]. Given these clin-
ical associations, postprandial hyperglycemia is closely re-
lated to both the risk and prognosis of cardiovascular
disease. Considering the close correlation between the
postprandial glucose level and CAD, a sensitive indicator
of postprandial hyperglycemia may be more conducive to
predicting the risk of CAD. Many studies have suggested
that both GA and 1,5-AG reflect postprandial hypergly-
cemia better than does HbA1c [17,25]. In line with
amounts of previous research [3-6,26], the present study
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CAD than HbA1c.
It is purportedly that the causes of the abnormal distri-
bution of peripheral blood lymphocytes play an important
role in the occurrence and development of atherosclerosis
[27]. Dworacka, et al. [28] found a correlation between
1,5-AG and abnormal distributions of CD4+ and CD8+28-
lymphocyte subsets in peripheral blood, and this correl-
ation was stronger than that of HbA1c and the fasting
blood glucose level. Ohira, et al. [29] showed that varia-
tions of 1,5-AG in response to the change of diabetic
treatment were associated with the cardio-ankle vascular
index, a known indicator of angiosclerosis. Furthermore,
an 11-year prospective study performed by Watanabe,
et al. [30] revealed that 1,5-AG was an independent risk
factor for cardiovascular disease in men. So did the
present study observe the close relationship between 1,5-
AG and CAD, which was consistent with the findings of
previous studies [6].
In the present study, GA was pointed out to be superior
to HbA1c and 1,5-AG when associated with CAD. As a
glycemic marker, GA is used to evaluate glycemic control
during the previous 2 to 3 weeks. Norimatsu, et al. [26] se-
lected 244 Japanese patients to undergo coronary com-
puted tomography angiography, finding that GA was
superior to HbA1c as a predictor of the presence of CAD.
Furusyo, et al. [31,32] selected 1575 subjects aged 26 to
78 years for their Kyushu and Okinawa Population Study,
finding that GA was positively associated with the carotid
intima-media thickness and served as a predictor of the
presence of atherosclerosis. A study of 218 Korean subjects
carried out by Song, et al. [33] suggested that GA was a
more valuable index than HbA1c for predicting the pro-
gression of atherosclerosis in patients with type 2 diabetes
mellitus. In a series of research with enrollment of Chinese
patients with type 2 diabetes mellitus undergoing coronary
angiography, GA was identified as an important predictor
of the presence and severity of CAD and exhibited predict-
ive value beyond HbA1c [3,4]. Moreover, the higher GA
level of type 2 diabetic patients concomitant with stable
angina and chronic total occlusion was reportedly asso-
ciated with the presence of diminished coronary collat-
eral flow. Regression analysis revealed that GA, but not
HbA1c, was independently associated with low coron-
ary collateralization [5].
As a predominant early Amadori-type glycation protein in
the circulation of patients with diabetes, GA plays a pivotal
role in the physiological mechanisms of diabetic atheroscler-
osis. The particular mechanisms can be explained as follows.
GA is transferred into advanced glycation end products in
high-glucose conditions, which is a critical factor responsible
for diabetic macrovascular complications. In addition, the
soluble receptor of advanced glycation end products is also
demonstrated to be an independent marker of CAD [34].GA causes destruction in endothelial cell function, leading
to oxidative stress and an inflammatory reaction in the ves-
sel walls along with the proliferation and migration of vascu-
lar smooth muscle cells. In this way, GA speeds up the
development and progression of atherosclerosis and vascular
complications of diabetes [32,35].Limitations
The present study has two main limitations. First, we only
recruited subjects admitted to the Department of Cardi-
ology to undergo coronary angiography, and all subjects
had already been on intervention therapy because of exist-
ing risk factors for CAD. This affected the results to some
extent. Whether our findings can be replicated in the gen-
eral population requires further confirmation. Second,
limited by the small sample size and cross-sectional de-
sign, this study was hard to find the acute sequence of the
increase in the GA level and occurrence of CAD. Further
large-scale prospective studies are needed to determine
whether GA is a suitable indicator for identifying CAD.Conclusions
GA displayed a more closely correlation with CAD than
did HbA1c and 1,5-AG in a Chinese population with high
risk of CAD. The findings of this study suggested that the
serum GA level was superior to HbA1c and 1,5-AG in
identifying CAD and that its measurement in patients with
high risk of CAD was helpful for early detection of cardio-
vascular disease. Not only identification of the underlying
connection between GA and atherosclerosis, but also
utility of GA as a monitoring indicator of glucose control
in diabetes management requires further investigation.
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